Nichi-Iko Pharmaceutical
Biosimilar developer, Japan. 2 development products across 2 molecules: bevacizumab, infliximab.
First approval in the Atlas: Sep 2017, Infliximab BS Nichiiko / AYUMI, infliximab (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved2
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Bevacizumab BS Nichi-Iko | · | · | Jan 2022 | · | · | · |
| Infliximab | Infliximab BS Nichiiko / AYUMI | · | · | Sep 2017 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Nichi-Iko Pharmaceutical is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Etanercept | Etanercept BS TY / Nichiiko | PMDA | Yoshindo; Nichi-Iko Pharmaceutical | Mar 2019 | Lupin |
Chronology
- PMDASep 2017Infliximab BS Nichiiko / AYUMI, infliximab
- PMDAJan 2022Bevacizumab BS Nichi-Iko, bevacizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.